Faeth Therapeutics, Inc. Comprehensive Income
Faeth Therapeutics, Inc. (FTH) reported Comprehensive Income of -$16.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$16.05M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$170.26M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$4.71M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$4.56M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$21.07M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$29.96M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$33.31M.
- Faeth Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$49.26M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.05M 10-Q · filed 2026-08-04 | -$186.31M 10-Q · filed 2026-08-04 | -$191.02M derived: sum of 3 quarters · filed 2026-08-04 | -$195.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$170.26M 10-Q · filed 2026-05-15 | -$174.97M derived: sum of 2 quarters · filed 2026-05-15 | -$179.53M derived: sum of 3 quarters · filed 2026-05-15 | -$184.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.27M derived: sum of 2 quarters · filed 2026-03-30 | -$14.21M derived: sum of 3 quarters · filed 2026-08-04 | -$21.07M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$4.56M 10-Q · filed 2025-11-14 | -$9.50M derived: sum of 2 quarters · filed 2026-08-04 | -$16.36M 10-Q · filed 2025-11-14 | -$24.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$4.94M 10-Q · filed 2026-08-04 | -$11.80M 10-Q · filed 2026-08-04 | -$19.59M derived: sum of 3 quarters · filed 2026-08-04 | -$26.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$6.86M 10-Q · filed 2026-05-15 | -$14.65M derived: sum of 2 quarters · filed 2026-05-15 | -$21.80M derived: sum of 3 quarters · filed 2026-05-15 | -$28.90M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$14.94M derived: sum of 2 quarters · filed 2026-03-30 | -$22.04M derived: sum of 3 quarters · filed 2026-03-30 | -$29.96M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$7.15M 10-Q · filed 2025-11-14 | -$14.24M derived: sum of 2 quarters · filed 2025-11-14 | -$22.16M 10-Q · filed 2025-11-14 | -$29.39M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$7.10M 10-Q · filed 2025-08-05 | -$15.02M 10-Q · filed 2025-08-05 | -$22.24M derived: sum of 3 quarters · filed 2025-08-05 | -$29.22M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$7.92M 10-Q · filed 2025-05-06 | -$15.14M derived: sum of 2 quarters · filed 2025-05-06 | -$22.12M derived: sum of 3 quarters · filed 2025-05-06 | -$31.23M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$14.20M derived: sum of 2 quarters · filed 2025-03-28 | -$23.31M derived: sum of 3 quarters · filed 2025-03-28 | -$33.31M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$6.98M 10-Q · filed 2024-11-14 | -$16.09M derived: sum of 2 quarters · filed 2024-11-14 | -$26.09M 10-Q · filed 2024-11-14 | -$38.12M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$9.11M 10-Q · filed 2024-08-06 | -$19.11M 10-Q · filed 2024-08-06 | -$31.14M derived: sum of 3 quarters · filed 2024-08-06 | -$44.55M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$10.00M 10-Q · filed 2024-05-09 | -$22.03M derived: sum of 2 quarters · filed 2024-05-09 | -$35.44M derived: sum of 3 quarters · filed 2024-05-09 | -$46.28M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$12.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$25.44M derived: sum of 2 quarters · filed 2024-02-29 | -$36.29M derived: sum of 3 quarters · filed 2024-02-29 | -$49.26M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$13.41M 10-Q · filed 2023-11-07 | -$24.26M derived: sum of 2 quarters · filed 2023-11-07 | -$37.23M 10-Q · filed 2023-11-07 | -$46.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$10.85M 10-Q · filed 2023-08-03 | -$23.82M 10-Q · filed 2023-08-03 | -$33.45M derived: sum of 3 quarters · filed 2023-08-03 | -$43.10M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.97M 10-Q · filed 2023-05-09 | -$22.60M derived: sum of 2 quarters · filed 2023-05-09 | -$32.25M derived: sum of 3 quarters · filed 2023-05-09 | -$42.13M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$19.28M derived: sum of 2 quarters · filed 2023-03-29 | -$29.16M derived: sum of 3 quarters · filed 2023-03-29 | -$37.13M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$9.65M 10-Q · filed 2022-11-08 | -$19.52M derived: sum of 2 quarters · filed 2022-11-08 | -$27.50M 10-Q · filed 2022-11-08 | -$32.73M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$9.87M 10-Q · filed 2022-08-09 | -$17.84M 10-Q · filed 2022-08-09 | -$23.08M derived: sum of 3 quarters · filed 2022-08-09 | -$28.45M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$7.97M 10-Q · filed 2022-05-10 | -$13.21M derived: sum of 2 quarters · filed 2022-05-10 | -$18.57M derived: sum of 3 quarters · filed 2022-05-10 | -$23.48M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$10.60M derived: sum of 2 quarters · filed 2022-03-15 | -$15.51M derived: sum of 3 quarters · filed 2022-03-15 | -$20.20M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$5.37M 10-Q · filed 2021-11-10 | -$10.28M derived: sum of 2 quarters · filed 2021-11-10 | -$14.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$4.91M 10-Q · filed 2021-08-11 | -$9.60M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |